atai Life Sciences Increases its Ownership Position in COMPASS Pathways Post published:November 29, 2021 Post category:Press Release
Psychedelic Bulletin: Microdosing Study Causes a Stir; COMPASS Secures 5th US Patent; Leave Toads Alone? Post published:November 26, 2021 Post category:Psychedelic Bulletin
Numinus Receives Conditional Approval to Graduate to the Toronto Stock Exchange Post published:November 26, 2021 Post category:Press Release
Numinus Announces Departure of Stacey Wallin Post published:November 25, 2021 Post category:Press Release
Seelos Therapeutics Raises $20 Million in Private Placement of Senior Secured Convertible Note Post published:November 24, 2021 Post category:Press Release
PharmaTher Applies for FDA Orphan Drug Designation for Ketamine to Treat Rare Neurological Disorder Status Epilepticus Post published:November 24, 2021 Post category:Press Release
Entheon Biomedical Provides Update on Clinical and Preclinical DMT Programs Post published:November 24, 2021 Post category:Press Release
COMPASS Pathways granted fifth US patent for crystalline psilocybin Post published:November 23, 2021 Post category:Press Release
Cybin Awards Grant for Psychedelic Treatment Clinic at Lenox Hill Hospital to Benefit Underserved Communities Post published:November 23, 2021 Post category:Press Release
Numinus to Host Q4 and 2021 Annual Results Conference Call on December 9, 2021 Post published:November 22, 2021 Post category:Press Release